{
  "id": "domain-3-ch13-sexual-dysfunctions",
  "name": "Ch 13: Sexual Dysfunctions",
  "domain": "Domain 3: Clinical Psychopathology",
  "questions": [
    {
      "type": "single-choice",
      "id": "d3-sgp-001",
      "stem": "A 35-year-old man reports persistent difficulty achieving erections sufficient for sexual activity for the past 8 months. The problem occurs in all situations. He has no medical conditions and takes no medications. Nocturnal penile tumescence testing shows normal erections during REM sleep. What does this finding most strongly suggest?",
      "options": [
        "Neurological erectile dysfunction",
        "Vascular erectile dysfunction",
        "Psychogenic erectile dysfunction",
        "Hormonal erectile dysfunction"
      ],
      "correctAnswer": 2,
      "explanation": "Normal nocturnal penile tumescence (NPT) during REM sleep indicates intact neurovascular mechanisms for erection. When NPT is normal but waking erections are impaired, this strongly suggests psychogenic (psychological) etiology. Organic causes (vascular, neurological, hormonal) would impair both nocturnal and waking erections.",
      "difficulty": "hard",
      "tags": [
        "erectile disorder",
        "NPT testing",
        "differential diagnosis"
      ]
    },
    {
      "type": "single-choice",
      "id": "d3-sgp-003",
      "stem": "A 42-year-old woman reports decreased sexual desire that began after starting sertraline for depression 6 months ago. Her relationship is stable and desire was normal before medication. According to DSM-5, what is the most appropriate diagnosis?",
      "options": [
        "Female sexual interest/arousal disorder",
        "Substance/medication-induced sexual dysfunction",
        "Other specified sexual dysfunction",
        "No diagnosis—medication side effects are expected"
      ],
      "correctAnswer": 1,
      "explanation": "When sexual dysfunction develops in temporal relationship to medication initiation and the medication is known to cause such effects, substance/medication-induced sexual dysfunction is diagnosed. SSRIs commonly cause decreased libido. This is coded separately from the primary sexual dysfunctions which require ruling out substance etiology.",
      "difficulty": "hard",
      "tags": [
        "medication-induced sexual dysfunction",
        "SSRI side effects",
        "DSM-5"
      ]
    },
    {
      "type": "multiple-choice",
      "id": "d3-sgp-006",
      "stem": "Which of the following are DSM-5 criteria for female orgasmic disorder? (Select all that apply)",
      "options": [
        "Marked delay in, infrequency, or absence of orgasm",
        "Markedly reduced intensity of orgasmic sensations",
        "Symptoms present for at least 6 months",
        "Problem occurs in all sexual situations",
        "Causes clinically significant distress"
      ],
      "correctAnswers": [
        0,
        1,
        2,
        4
      ],
      "explanation": "Female orgasmic disorder requires: (A) orgasmic delay/infrequency/absence OR reduced intensity in nearly all (75-100%) sexual occasions, (B) ≥6 months duration, (C) clinically significant distress, and (D) not better explained by other factors. Specifiers indicate whether it's lifelong/acquired and generalized/situational—it does NOT require problems in all situations.",
      "difficulty": "hard",
      "tags": [
        "female orgasmic disorder",
        "DSM-5 criteria",
        "sexual dysfunction"
      ]
    },
    {
      "type": "multiple-choice",
      "id": "d3-sgp-007",
      "stem": "Which treatment approaches have the strongest evidence base for erectile disorder? (Select all that apply)",
      "options": [
        "Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)",
        "Cognitive-behavioral sex therapy",
        "Testosterone replacement when levels are low",
        "Psychodynamic exploration of castration anxiety",
        "Sensate focus exercises"
      ],
      "correctAnswers": [
        0,
        1,
        2,
        4
      ],
      "explanation": "Evidence-based treatments for erectile disorder include: PDE5 inhibitors (first-line pharmacotherapy), CBT-based sex therapy (addressing performance anxiety, cognitive distortions), testosterone when documented hypogonadism, and sensate focus (reducing performance pressure). Psychodynamic approaches lack strong empirical support for sexual dysfunctions compared to behavioral interventions.",
      "difficulty": "hard",
      "tags": [
        "erectile disorder",
        "evidence-based treatment",
        "PDE5 inhibitors"
      ]
    },
    {
      "type": "multiple-choice",
      "id": "d3-sgp-010",
      "stem": "Which statements about genito-pelvic pain/penetration disorder are accurate according to DSM-5? (Select all that apply)",
      "options": [
        "It combines former diagnoses of dyspareunia and vaginismus",
        "It can only be diagnosed in women",
        "Persistent difficulties must occur on 75-100% of penetration attempts",
        "Fear or anxiety about pain is a diagnostic criterion",
        "Minimum duration of 6 months is required"
      ],
      "correctAnswers": [
        0,
        2,
        3,
        4
      ],
      "explanation": "Genito-pelvic pain/penetration disorder (GPPPD) combines former dyspareunia and vaginismus into one diagnosis. It requires persistent difficulty with: penetration, pain, fear/anxiety about pain, or pelvic floor muscle tensing—occurring on ≥75% of attempts for ≥6 months. While rare in men, it is NOT limited to women in DSM-5 criteria.",
      "difficulty": "hard",
      "tags": [
        "genito-pelvic pain",
        "DSM-5 changes",
        "sexual pain disorders"
      ]
    },
    {
      "type": "matrix-single",
      "id": "d3-sgp-011",
      "stem": "Match each sexual dysfunction with its primary symptom domain.",
      "rows": [
        "Delayed ejaculation",
        "Female sexual interest/arousal disorder",
        "Premature ejaculation",
        "Genito-pelvic pain/penetration disorder"
      ],
      "columns": [
        "Orgasm phase difficulty",
        "Desire/arousal deficit",
        "Ejaculatory timing dysfunction",
        "Pain or penetration difficulty"
      ],
      "correctAnswers": {
        "Delayed ejaculation": "Orgasm phase difficulty",
        "Female sexual interest/arousal disorder": "Desire/arousal deficit",
        "Premature ejaculation": "Ejaculatory timing dysfunction",
        "Genito-pelvic pain/penetration disorder": "Pain or penetration difficulty"
      },
      "explanation": "Sexual response domains: Delayed ejaculation involves orgasmic phase (marked delay/infrequency/absence). FSIAD involves desire/arousal (lack of interest/arousal). Premature ejaculation is ejaculatory timing (before desired). GPPPD involves pain/penetration difficulties (pain, fear, muscle tensing). These reflect distinct phases of sexual response cycle.",
      "difficulty": "hard",
      "tags": [
        "sexual dysfunctions",
        "symptom domains",
        "classification"
      ]
    },
    {
      "type": "matrix-multiple",
      "id": "d3-sgp-013",
      "stem": "For each medication class, select ALL sexual dysfunction side effects it commonly causes.",
      "rows": [
        "SSRIs",
        "Antipsychotics (typical)",
        "Antihypertensives (beta-blockers)"
      ],
      "columns": [
        "Decreased libido",
        "Erectile dysfunction",
        "Delayed/absent orgasm",
        "Hyperprolactinemia-related dysfunction"
      ],
      "correctAnswers": {
        "SSRIs": [
          "Decreased libido",
          "Delayed/absent orgasm"
        ],
        "Antipsychotics (typical)": [
          "Decreased libido",
          "Erectile dysfunction",
          "Hyperprolactinemia-related dysfunction"
        ],
        "Antihypertensives (beta-blockers)": [
          "Erectile dysfunction"
        ]
      },
      "explanation": "SSRIs commonly cause decreased desire and anorgasmia/delayed orgasm via serotonergic effects. Typical antipsychotics cause multiple dysfunctions through D2 blockade causing hyperprolactinemia (decreased libido, ED) and anticholinergic effects. Beta-blockers primarily cause ED through decreased sympathetic tone and blood flow effects.",
      "difficulty": "hard",
      "tags": [
        "medication-induced sexual dysfunction",
        "side effect profiles",
        "pharmacology"
      ]
    },
    {
      "type": "matrix-multiple",
      "id": "d3-sgp-014",
      "stem": "For each treatment modality, select ALL conditions for which it has evidence support.",
      "rows": [
        "Sensate focus exercises",
        "PDE5 inhibitors",
        "Cognitive-behavioral therapy"
      ],
      "columns": [
        "Erectile disorder",
        "Female orgasmic disorder",
        "Premature ejaculation",
        "Genito-pelvic pain disorder"
      ],
      "correctAnswers": {
        "Sensate focus exercises": [
          "Erectile disorder",
          "Female orgasmic disorder",
          "Genito-pelvic pain disorder"
        ],
        "PDE5 inhibitors": [
          "Erectile disorder"
        ],
        "Cognitive-behavioral therapy": [
          "Erectile disorder",
          "Female orgasmic disorder",
          "Premature ejaculation",
          "Genito-pelvic pain disorder"
        ]
      },
      "explanation": "Sensate focus helps ED (reduces performance anxiety), female orgasmic disorder (increases awareness), and GPPPD (gradual exposure). PDE5 inhibitors are specifically for ED (mechanism of action targets erectile physiology). CBT has evidence for all listed conditions—addressing cognitive distortions, anxiety, and behavioral patterns across sexual dysfunctions.",
      "difficulty": "hard",
      "tags": [
        "sexual dysfunction treatment",
        "evidence-based interventions",
        "treatment matching"
      ]
    },
    {
      "type": "cloze-dropdown",
      "id": "d3-sgp-015",
      "stem": "A 30-year-old man experiences ejaculation within 30 seconds of vaginal penetration on 90% of occasions over the past year. This causes significant distress. The DSM-5 diagnosis is [[1]]. Behavioral treatment would include [[2]]. The most commonly used pharmacological intervention is [[3]].",
      "options": {
        "1": [
          "Premature ejaculation",
          "Male hypoactive sexual desire disorder",
          "Delayed ejaculation",
          "Erectile disorder"
        ],
        "2": [
          "Stop-start technique and squeeze technique",
          "Sensate focus with penetration prohibition",
          "Directed masturbation training",
          "Systematic desensitization to sexual stimuli"
        ],
        "3": [
          "Daily or on-demand SSRI",
          "PDE5 inhibitor",
          "Testosterone supplementation",
          "Buspirone"
        ]
      },
      "correctAnswers": {
        "1": "Premature ejaculation",
        "2": "Stop-start technique and squeeze technique",
        "3": "Daily or on-demand SSRI"
      },
      "explanation": "Ejaculation within 1 minute on nearly all occasions with distress meets criteria for premature (early) ejaculation. Behavioral treatments include stop-start (pausing stimulation at high arousal) and squeeze technique (applying pressure to reduce arousal). SSRIs (daily or on-demand dapoxetine where available) are primary pharmacotherapy due to orgasm-delaying side effect.",
      "difficulty": "hard",
      "tags": [
        "premature ejaculation",
        "behavioral treatment",
        "SSRI"
      ]
    },
    {
      "type": "bowtie",
      "id": "d3-sgp-017",
      "stem": "A 45-year-old woman presents with lack of sexual interest, no sexual thoughts or fantasies, and no response to partner initiation for the past 2 years. She had normal desire before this period. She is not taking medications and has no medical conditions. Her relationship is satisfying otherwise.",
      "centerStatement": "Most likely diagnosis",
      "leftColumn": {
        "header": "Key Diagnostic Features",
        "options": [
          "Absent or reduced interest in sexual activity",
          "Absent or reduced erotic thoughts/fantasies",
          "Acquired onset (was previously normal)",
          "Duration exceeds 6 months"
        ]
      },
      "rightColumn": {
        "header": "Important Assessment Areas",
        "options": [
          "Relationship quality and partner factors",
          "Hormonal status (estrogen, testosterone)",
          "Depression and anxiety screening",
          "Performance anxiety about orgasm"
        ]
      },
      "correctAnswers": {
        "center": "Female sexual interest/arousal disorder",
        "left": [
          "Absent or reduced interest in sexual activity",
          "Absent or reduced erotic thoughts/fantasies",
          "Acquired onset (was previously normal)",
          "Duration exceeds 6 months"
        ],
        "right": [
          "Relationship quality and partner factors",
          "Hormonal status (estrogen, testosterone)",
          "Depression and anxiety screening"
        ]
      },
      "explanation": "This meets FSIAD criteria: reduced interest, reduced fantasies, acquired (specifier), generalized, >6 months. Assessment should include relationship factors, hormones (perimenopause), and mood (depression commonly presents with low libido). Performance anxiety about orgasm is less relevant to desire/arousal disorders and more relevant to orgasmic disorders.",
      "difficulty": "hard",
      "tags": [
        "female sexual interest/arousal disorder",
        "assessment",
        "differential diagnosis"
      ]
    },
    {
      "type": "highlight",
      "id": "d3-sgp-019",
      "stem": "Highlight ALL DSM-5 diagnostic criteria for male hypoactive sexual desire disorder.",
      "passage": "The patient demonstrates persistently or recurrently deficient or absent sexual/erotic thoughts or fantasies and desire for sexual activity as judged by clinician considering age and sociocultural context. The symptoms have persisted for a minimum duration of approximately 6 months. The symptoms cause clinically significant distress in the individual. The patient also reports erectile difficulties occurring about 30% of the time. The sexual dysfunction is not better explained by a nonsexual mental disorder or relationship distress or other significant stressors and is not attributable to effects of a substance or medication or another medical condition. The patient reports his partner has higher sexual desire than he does.",
      "correctHighlights": [
        "persistently or recurrently deficient or absent sexual/erotic thoughts or fantasies and desire for sexual activity",
        "minimum duration of approximately 6 months",
        "cause clinically significant distress",
        "not better explained by a nonsexual mental disorder or relationship distress or other significant stressors",
        "not attributable to effects of a substance or medication or another medical condition"
      ],
      "explanation": "DSM-5 criteria for male HSDD: (A) deficient/absent desire and erotic thoughts, (B) ≥6 months duration, (C) clinically significant distress, (D) not better explained by other mental disorder, relationship, or stressors, (E) not substance/medication/medical condition. Erectile difficulties and partner desire discrepancy are additional clinical information but not HSDD criteria.",
      "difficulty": "hard",
      "tags": [
        "male hypoactive sexual desire disorder",
        "DSM-5 criteria",
        "sexual dysfunction"
      ]
    },
    {
      "type": "highlight",
      "id": "d3-sgp-020",
      "stem": "Highlight ALL statements that describe empirically supported treatment approaches for sexual dysfunctions.",
      "passage": "Treatment approaches include sensate focus exercises developed by Masters and Johnson which reduce performance anxiety through graduated touching without pressure for intercourse. Cognitive restructuring addresses maladaptive beliefs about sexual performance and unrealistic expectations. Directed masturbation training has strong evidence for female orgasmic disorder, teaching women to identify pleasurable sensations. PDE5 inhibitors like sildenafil have robust evidence for erectile disorder by enhancing nitric oxide-mediated vasodilation. Psychoanalytic exploration of unconscious oedipal conflicts is the first-line treatment for most dysfunctions. The stop-start technique helps men with premature ejaculation learn to recognize and manage arousal levels. Systemic couple therapy addresses relational factors contributing to sexual problems. Vaginal dilators with gradual progression are used for genito-pelvic pain/penetration disorder.",
      "correctHighlights": [
        "sensate focus exercises developed by Masters and Johnson which reduce performance anxiety through graduated touching without pressure for intercourse",
        "Cognitive restructuring addresses maladaptive beliefs about sexual performance and unrealistic expectations",
        "Directed masturbation training has strong evidence for female orgasmic disorder",
        "PDE5 inhibitors like sildenafil have robust evidence for erectile disorder",
        "stop-start technique helps men with premature ejaculation learn to recognize and manage arousal levels",
        "Systemic couple therapy addresses relational factors contributing to sexual problems",
        "Vaginal dilators with gradual progression are used for genito-pelvic pain/penetration disorder"
      ],
      "explanation": "Evidence-based treatments: sensate focus (reduced performance anxiety), cognitive restructuring (CBT component), directed masturbation (female orgasmic disorder gold standard), PDE5 inhibitors (ED), stop-start/squeeze (PE), couple therapy (relational factors), and vaginal dilators (GPPPD). Psychoanalytic exploration of oedipal conflicts lacks empirical support as first-line treatment.",
      "difficulty": "hard",
      "tags": [
        "sexual dysfunction treatment",
        "evidence-based practice",
        "treatment approaches"
      ]
    },
    {
      "type": "drag-drop-ordered",
      "id": "d3-sgp-021",
      "stem": "Arrange the steps of sensate focus therapy in the correct sequential order.",
      "options": [
        "Non-genital touching with focus on sensations, not arousal",
        "Genital touching included but no penetration or orgasm goal",
        "Discussion of communication and reducing performance pressure",
        "Gradual progression to penetration if desired",
        "Temporary prohibition on intercourse and orgasm-focused activity"
      ],
      "correctOrder": [
        2,
        4,
        0,
        1,
        3
      ],
      "explanation": "Sensate focus proceeds: (1) psychoeducation about reducing pressure and improving communication, (2) temporary intercourse prohibition to remove performance demand, (3) non-genital pleasuring focusing on sensations, (4) addition of genital touching without orgasm pressure, (5) gradual return to penetration as anxiety decreases. This graduated approach was developed by Masters and Johnson.",
      "difficulty": "hard",
      "tags": [
        "sensate focus",
        "sex therapy",
        "treatment protocol"
      ]
    },
    {
      "type": "drag-drop-ordered",
      "id": "d3-sgp-022",
      "stem": "Arrange the steps of directed masturbation treatment for female orgasmic disorder in the correct order.",
      "options": [
        "Education about female sexual anatomy and response",
        "Visual and tactile self-exploration without arousal goal",
        "Self-stimulation focusing on pleasurable areas",
        "Intensify stimulation to achieve orgasm",
        "Transfer learning to partner sexual activity"
      ],
      "correctOrder": [
        0,
        1,
        2,
        3,
        4
      ],
      "explanation": "Directed masturbation progresses: (1) education about anatomy/response (demystifying), (2) non-sexual self-exploration (comfort with body), (3) focused self-stimulation (identifying pleasurable sensations), (4) increasing stimulation to orgasm (goal attainment), (5) bridging to partner activity (generalization). This is the most empirically supported treatment for primary anorgasmia.",
      "difficulty": "hard",
      "tags": [
        "directed masturbation",
        "female orgasmic disorder",
        "treatment protocol"
      ]
    },
    {
      "type": "trend-analysis",
      "id": "d3-sgp-023",
      "stem": "A man receiving treatment for premature ejaculation tracks his intravaginal ejaculatory latency time (IELT) over 8 weeks:\n\nWeek 0: 30 seconds\nWeek 2: 45 seconds\nWeek 4: 1 minute 15 seconds\nWeek 6: 2 minutes\nWeek 8: 3 minutes 30 seconds\n\nWhat does this trajectory indicate?",
      "trendData": {
        "labels": [
          "Week 0",
          "Week 2",
          "Week 4",
          "Week 6",
          "Week 8"
        ],
        "values": [
          0.5,
          0.75,
          1.25,
          2,
          3.5
        ]
      },
      "options": [
        "Treatment failure requiring medication change",
        "Progressive improvement consistent with effective behavioral therapy",
        "Normal variation without meaningful clinical change",
        "Improvement followed by plateau requiring intervention change"
      ],
      "correctAnswer": 1,
      "explanation": "IELT improved from 30 seconds to 3.5 minutes over 8 weeks—a 7-fold increase representing clinically meaningful progress. This progressive improvement pattern is consistent with effective behavioral treatment (stop-start, squeeze technique). The trajectory shows continuing improvement rather than plateau, suggesting treatment should continue.",
      "difficulty": "hard",
      "tags": [
        "premature ejaculation",
        "treatment outcome",
        "IELT"
      ]
    }
  ]
}
